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ABSTRACT
The aim of the present study was to examine the relationship between tumour 
NF-κB activation, tumour microenvironment including local inflammatory response 
(LIR) and cancer-specific survival in patients with operable ductal breast cancer.
Immunohistochemistry (tissue microarray of 376 patients) and western blotting 
(MCF7 and MDA-MB-231 breast cancer cells) was performed to assess expression of 
key members of the canonical NF-κB pathway (inhibitory kappa B kinase (IKKβ) and 
phosphorylated p65 Ser-536 (p-p65)). Following silencing of IKKβ, cell viability and 
apoptosis was assessed in both MCF7 and MDA-MB-231 cell lines.
P-p65 was associated with cancer-specific survival (CSS) (nuclear P=0.042 and 
total P=0.025). High total p-p65 was associated with increase grade tumour grade 
(P=0.010), ER positivity (P=0.023), molecular subtype (P=0.005), lower Klintrup-
Makinen grade (P=0.013) and decreased CD138 count (P=0.032). On multivariate 
analysis, total p-p65 expression independently associated with poorer CSS (P=0.020). 
In vitro work demonstrated that the canonical NF-κB pathway was inducible by 
exposure to TNFα in ER-positive MCF7 cells and to a lesser extent in ER-negative MDA-
MB-231 cells. Reduction of IKKβ expression by siRNA transfection increased levels of 
apoptosis and reduced cell viability in both MCF7 (P=<0.001, P=<0.001, respectively) 
and MDA-MB-231 cells (P=>0.001, P=0.002, respectively). This is consistent with the 
hypothesis that canonical IKKβ-NF-κB signalling drives tumour survival.
These results suggest that activation of the canonical NF-κB pathway is an 
important determinant of poor outcome in patients with invasive ductal breast cancer.
INTRODUCTION
Breast cancer is the most common female cancer 
in the UK and, despite earlier detection and improved 
treatments, remains the second most common cause of 
cancer death in women [1, 2]. Therefore, it is clear that a 
further understanding of this disease process is required.
For many years an association between cancer and 
inflammation has been suspected and evidence has been 
gathered over the last decade to support this relationship [3, 
4]. However, little is known about the signalling pathways 
that link these processes. The canonical mammalian Nuclear 
Factor kappa B (NF-κB) pathway regulates genes involved 
in many of the processes considered as hallmarks of cancer 
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including inflammation, proliferation and apoptosis [5, 6]. It 
is therefore not surprising that NF-κB has been hypothesised 
to provide the link between inflammation and cancer [6–9].
Aberrant activity of various NF-κB components 
has been observed in a number of solid tumours including 
colorectal [10] and prostate cancer [11–13]. In breast 
cancer, increased NF-κB activity has been observed in rat 
mammary tumours compared to normal tissue [14] and 
numerous studies employing cell lines have reported an 
association with NF-κB activity and endocrine resistance 
[15]. In human breast cancer specimens, expression of the 
different NF-κB subunits have been observed [14, 15]. 
Levels of phosphorylated p65 have been reported to correlate 
with HER2 expression, tumour size, grade and presence of 
metastases in a cohort of 57 patients [15] and high DNA 
binding activity of p50 was associated with decreased disease 
free survival in a cohort of 81 cases [17]. In a larger cohort 
of 208 cases, p65 expression was not associated with disease 
specific survival but was associated with luminal B subtype 
[16]. A clear consensus of the prognostic power of members 
of the canonical NF-κB pathway has not been reached.
Therefore the aims of the present study are to 
examine the relationship between key members of the 
canonical NF-κB pathway (IKKα and p65 (RelA)), local 
inflammatory infiltrate and survival in a cohort of patients 
with primary operable invasive ductal breast cancer.
RESULTS
A total of 376 patients who presented with invasive 
ductal breast cancer were included in the study. Seventy 
three patients had local or distant recurrences, the median 
follow-up of survivors was 164 months with 79 cancer-
associated deaths and 79 non-cancer deaths. ER, PR, HER2 
and Ki67 status was available for these patients allowing 
us to determine molecular subtype: 44% of patients had 
Luminal A disease (ER and PR positive, HER2 negative and 
low Ki67 <14%), 21% had Luminal B disease (ER, PR and 
HER2 positive or ER, PR and high Ki67 (>14%)), 21% had 
triple negative disease (ER, PR and HER2 negative) and 12% 
with HER2 enriched disease (ER and PR negative, HER2 
positive). We were unable to define molecular subtype in 2% 
of cases due to missing data.
Expression of IKKβ was observed in the cytoplasm 
and ranged from 0-275 weighed histoscore units 
(Supplementary Figure 1). P-p65 expression was observed 
in the cytoplasm ranging from 0-220 histoscore units and the 
nucleus ranging from 0-160 histoscore units (Supplementary 
Figure 2). Expression was split into tertiles, the first tertile 
was considered low expression and the second and third 
tertiles were grouped to provide a measure of moderate/high 
expression. Expression of IKKβ was not associated with 
cancer-specific survival (Figure 1A) (P=0.903), cytoplasmic 
p-p65 expression showed a non-significant trend towards 
shorter cancer-specific survival (Figure 1B, Table 2) 
(P=0.052) and nuclear p-p65 expression showed a significant 
association with shorter cancer-specific survival (Figure 1C) 
(P=0.042). For nuclear p-p65 10 year cancer-specific survival 
was stratified from 84% to 71% (P=0.022).
When patients were subdivided by molecular 
subtype, no significant associations were observed 
between IKKβ or cytoplasmic p-p65 expression in any of 
the molecular subtypes. When nuclear p-p65 was stratified 
by molecular subtype (Figure 1D-1G) the only subtype 
where the association with cancer-specific survival was 
upheld was in patients with Luminal B disease (P=0.018) 
(Figure 1E), 10 year cancer-specific survival was stratified 
from 83% to 57% (P=0.006). A trend towards cancer-
specific survival was observed in the triple negative 
subgroup, however due to low patient numbers this did 
not reach significance (P=0.120). No association between 
nuclear p-p65 and cancer-specific survival was observed 
in patients with Luminal A disease (Figure 1D) (P=0.972) 
or HER2 enriched disease (Figure 1G) (P=0.868).
As nuclear p-p65 was associated with cancer-
specific survival, the relationship between this and tumour 
characteristics was subsequently examined (Table 1). High 
expression of nuclear p-p65 was associated with a high 
tumour grade (P=0.04) and tumour recurrence (P=0.008), 
but not tumour size, ER status, HER2 status or molecular 
subtype (Table 1). When associations with the tumour 
microenvironment were investigated, nuclear p-p65 
expression was not significantly associated with tumour 
budding, T-lymphocytes or Klintrup-Makinen grade. 
However an association was observed with increasing 
tumour stromal percentage (P=0.033) (Table 1).
When nuclear p-p65 was entered into a multivariate 
model using a backwards conditional method with 
clinicopathological parameters, nuclear p-p65 expression 
was not independently associated with cancer-specific 
survival in the full cohort (Table 2) but was independently 
associated with cancer-specific survival in Luminal B 
disease (P=0.019, HR 1.95 (1.12-3.41)).
To examine the relationship of cancer-specific 
survival and total tumour cell p-p65, a cumulative 
prognostic score of cytoplasmic and nuclear p-p65 was 
examined. Patients with both low cytoplasmic and nuclear 
expression were classified as the low expression group and 
patients with either moderate/high cytoplasmic or nuclear 
expression were classified as the moderate/high expression 
group. Moderate/high expression of total tumour cell 
expression of p-p65 was significantly association with 
shorter cancer-specific survival (Figure 2A) (P=0.025) 
and 10 year cancer-specific survival was stratified from 
86% (low expression) to 75% (moderate/high expression) 
(P=0.006). When total tumour cell p-p65 was stratified by 
molecular subtype (Figure 2B-2E) the association between 
total tumour cell p-p65 and cancer-specific survival was 
lost in patients with Luminal A disease (Figure 2B)
(P=0.712) (10 year survival, 90% vrs 92%, P=0.930) 
and in patients with HER2 enriched disease (Figure 2E) 
(P=0.992) (10 year survival, 67% vrs 59%, P=0.865). 
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However a trend towards cancer-specific survival was 
observed in patients with Luminal B disease (Figure 2C)
(P=0.142) (10 year survival, 78% vrs 55%, P=0.091) and 
in triple negative disease (Figure 2D) (P=0.109) (10 year 
survival, 90% vrs 66%, P=0.071), however due to low 
patient numbers these did not reach significance.
As total tumour cell p-p65 was associated with cancer-
specific survival, the relationship between this prognostic 
model and tumour characteristics was subsequently 
examined (Table 3). High expression of total tumour cell 
expression of p-p65 was associated with a high tumour 
grade (P=0.01), ER positive disease (P=0.023), molecular 
subtype (P=0.005) and tumour recurrence (P=0.001). When 
associations with the tumour microenvironment were 
investigated, high total tumour cell expression was not 
significantly associated with tumour stromal percentage, 
tumour budding or T-lymphocytes. However an association 
was observed with local inflammatory cell infiltrate as 
assessed by Klintrup-Makinen grade (P=0.013) and density 
of CD138+ B-lymphocytes (P=0.032).
When total tumour cell p-p65 was entered into a 
multivariate model using a backwards conditional method 
with clinicopathological parameters, total tumour cell p-p65 
expression was independently associated with disease-free 
survival (HR 1.25(1.03-1.53), P=0.024) (Table 2).
Does IKKβ silencing impact on breast cancer cell 
phenotype?
In the current study we report that activation of the 
canonical NF-κB pathway, measured by nuclear p-p65 
expression and total tumour cell p-p65 expression, is 
associated with reduced cancer-specific survival. Therefore 
the next aim was to establish if inhibition of the canonical 
NF-κB pathway could offer a possible therapeutic option. 
MCF7 cells were chosen to represent ER positive breast 
tumours and MDA-MB-231 were chosen to represent ER 
negative breast tumours.
It was first established that the canonical NF-κB 
pathway was inducible in both cell lines. This was 
Figure 1: (A) shows the relationship between IKKβ expression and cancer-specific survival in patients with primary operable invasive 
ductal breast cancer (P=0.903). (B) shows the relationship between cytoplasmic p-p65 expression and cancer-specific survival in patients 
with primary operable invasive ductal breast cancer (P=0.052). (C) shows the relationship between nuclear p-p65 expression and cancer-
specific survival in patients with invasive ductal breast cancer (P=0.042). (D) shows the relationship between nuclear p-p65 expression 
and cancer-specific survival in patients with Luminal A invasive ductal breast cancer (P=0.972). (E) shows the relationship between 
nuclear p-p65 expression and cancer-specific survival in patients with Luminal B invasive ductal breast cancer (P=0.018). (F) shows the 
relationship between nuclear p-p65 expression and cancer-specific survival in patients with triple negative invasive ductal breast cancer 
(P=0.120). (G) shows the relationship between nuclear p-p65 expression and cancer-specific survival in patients with HER2 enriched 
invasive ductal breast cancer (P=0.868).
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achieved by treating the cells with TNFα, which is 
known to stimulate the canonical pathway. In MCF7, 
ER positive breast cancer cells, TNFα exposure induced 
IκBα degradation and phosphorylation of p65 in a 
time dependent manner (Figure 3A). Following TNFα 
exposure, IκBα expression was reduced compared to 
control at 15 minutes and 30 minutes and phosphorylation 
of p65 (p-p65) was increased compared to control at 15 
minutes and 30 minutes. Levels of p65 and IKKβ were 
unchanged by TNFα exposure.
In MDA-MB-231, ER negative breast cancer 
cells, TNFα exposure induced IκBα degradation but to a 
lesser extent than that observed in the MCF7 cells and no 
increase in phosphorylation of p65 (p-p65) was observed 
(Figure 3B). Following TNFα exposure, IκBα expression 
was reduced compared to control at 15 minutes and 30 
minutes. Levels of p65 and IKKβ were unchanged by 
TNFα exposure.
Having established that the canonical NF-κB 
pathway was active in both cell types, and inducible to 
a much greater extent in MCF7 cells, the next aim of 
the study was to assess the impact on cell viability by 
inhibiting the pathway via silencing of IKKβ.
MCF7 and MDA-MB-231 cells were transfected 
with 200nM non-targeting (NT) siRNA or 200nM IKKβ 
siRNA, and 48 hours post treatment an apoptosis assay 
Table 1: The relationship between clinicopathological characteristics and nuclear p-p65 expression in patients with 
invasive ductal breast cancer
Patients n=376 low
(n=126)
high
(n=250)
P
Age (≤50/ >50 years) 36/90 72/178 0.963
Size (≤20/ 21-50/ >50 mm) 71/51/3 142/102/6 1.000
Grade (I / II / III) 27/56/43 40/97/113 0.040
Involved lymph node (negative/positive) 62/64 134/111 0.186
ER status (no/yes) 44/82 89/161 0.495
PR status (no/yes) 70/56 133/117 0.374
HER2 status (no/ yes) 100/23 200/49 0.470
Molecular subtype (Luminal A/Luminal B/triple 
negative/HER2 enriched)
54/29/25/15 111/50/55/29 0.897
Tumour necrosis (low/high) 54/69 105/140 0.486
Lymph vessel invasion (no/yes) 85/41 160/89 0.309
Blood vessel invasion (no/yes) 108/18 221/28 0.246
Klintrup–Mäkinen grade (weak/strong) 89/34 174/71 0.444
CD68+ (low/moderate/high) 34/45/46 61/95/93 0.705
CD4+ (low/moderate/high) 52/25/48 99/58/92 0.968
CD8+ (low/moderate/high) 26/47/52 73/92/84 0.058
CD138+ (low/moderate/high) 72/14/39 129/35/85 0.382
Angiogenesis (low/moderate/high) 37/44/42 78/81/82 0.789
Tumour stroma percentage (low/high) 82/42 138/110 0.033
Tumour budding (low/high) 79/47 162/87 0.367
Locoregional treatment 
(lumpectomy+radiotherapy/mastectomy+ 
radiotherapy)
39/87 97/153 0.083
Systemic treatment (hormonal/hormonal+ 
chemotherapy/chemotherapy/ none)
66/28/25/6 125/51/58/11 0.641
Recurrence (no recurrence/recurrence) 104/20 180/69 0.008
Bold indicates a significant association. Number of patients with missing data is not displayed, when values do not give a 
sum of 100% this is due to data being unavailable.
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or cell viability assay was performed (Figure 4A). A 
significant increase in apoptosis was observed in cells 
treated with siRNA to silence expression of IKKβ 
compared to the NT control (MCF7 cells, P<1.0x10-6 and 
MDA-MB-231 cells, P=2x10-4, Figure 4B) and a decrease 
in cell viability was observed in cells treated with siRNA 
to silence expression of IKKβ compared to the NT control 
(MCF7 cells, P=4.6x10-5 and MDA-MB-231, P=0.002, 
Figure 4C). Cell viability was also measured using the 
xCELLigence machine, and cell index graphs following 
silencing in MCF7 and MDA-MB-231 cells (Figure 4D) 
plotted. Both cell types treated with siRNA to silence 
expression of IKKβ had reduced cell viability compared 
to both untreated control (C) and NT control (Figure 4D).
DISCUSSION
In the present study expression of key members 
of the canonical NF-κB pathway were investigated to 
establish if there was a link between the canonical NF-ĸB 
pathway, local inflammatory infiltrate and cancer-specific 
survival in a cohort of patients with primary operable 
invasive ductal breast cancer. Phosphorylation of p65 at 
serine 536 (p-p65) was employed as a marker of activation 
of the canonical NF-κB pathway as it is important for 
transcriptional activation of the NF-ĸB dimer [26, 27]. 
High expression of p-p65 in the cytoplasm exhibited 
a non-significant trend towards a decrease in cancer-
specific survival and high nuclear p-p65 was significantly 
Table 2: The relationship between clinicopathological characteristics, nuclear p-p65 and cancer-specific survival in 
patients with invasive ductal breast cancer
Univariate analysis Multivariate analysis 
Nuclear p-p65
Multivariate analysis
Total tumour cell p-p65
Patients (n=376) Hazard ratio
(95% CI)
P value Hazard ratio
(95% CI)
P value Hazard ratio
(95% CI)
P value
Age (≤50/ >50 years) 1.33(0.812-2.24) 0.248
Size (≤20/ 21-50/ >50 mm) 1.72(1.16-2.56) 0.007
Grade (I / II / III) 1.94(1.37-2.75) <0.001
Involved lymph node 
(no/yes)
3.34(2.04-5.47) <0.001 2.39(1.40-4.07) 0.001 2.13(1.23-3.68) 0.007
ER status (no/yes) 0.46(0.29-0.72) 0.001
PR status (no/yes) 0.37(0.22-0.61) <0.001 0.43(0.25-0.730) 0.002 0.44(0.25-0.74) 0.002
HER2 status (no/ yes) 2.15(1.33-3.48) 0.002
Tumour necrosis (low/high) 4.33(2.41-7.94) <0.001 3.71 (1.97-6.97) <0.001 3.51(1.90-6.74) <0.001
Lymph vessel invasion 
(no/yes)
3.59(2.28-5.66) <0.001
Blood vessel invasion 
(no/yes)
3.01(1.79-5.06) <0.001 2.42(1.38-4.24) 0.002 2.19(1.23-3.90) 0.007
Klintrup–Mäkinen grade 
(week/strong)
1.32(0.82-2.13) 0.249
CD68+ (low/moderate/high) 0.78(0.59-1.04) 0.093
CD4+ (low/moderate/high) 1.00(0.782-1.28) 0.938
CD8+ (low/moderate/high) 0.62(0.46-0.82) 0.001 0.54(0.40-0.74) <0.001 0.54(0.40-0.72) <0.001
CD138+ (low/moderate/
high)
1.36(1.07-1.73) 0.01 1.461.11-1.91) 0.005 1.41(1.09-1.87) 0.009
Tumour stroma percentage 
(low/high)
1.26(1.44-3.54) <0.001 2.12(1.32-3.41) 0.002 2.10(1.30-3.38) 0.002
Tumour budding (low/high) 2.45(1.57-3.82) <0.001 2.12(1.31-3.42) 0.002 1.79(1.07-2.97) 0.025
Nuclear p-p65 (low/high) 1.29(1.00-1.67) 0.045 1.31(0.99-1.73) 0.057 NA NA
Total Tumour cell p-p65 
(both low/ one high)
1.21(1.02-1.44) 0.029 NA NA 1.25(1.03-1.53) 0.024
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associated with patient cancer-specific survival, recurrence 
and tumour grade. However no associations were made 
with nuclear p-p65 and inflammatory infiltrate, suggesting 
that this pathway is not responsible for regulating the 
local inflammatory response, but perhaps acting via an 
alternative mechanism such as proliferation.
Of additional interest was the observation that 
nuclear p-p65 was most strongly associated with cancer-
specific survival in ER positive, Luminal B tumours. There 
are four main subtypes of breast cancer that are considered 
clinically relevant (Luminal A, Luminal B, HER2 
enriched and triple negative). All subtypes have different 
molecular profiles and varied responses to endocrine 
therapy, HER2 targeted therapy and chemotherapy [3]. 
Differences in the biology of these subtypes are reflected 
in the results from this study, as activation of the NF-κB 
pathway has diverging roles in the different subtypes. 
The present study demonstrates that the association of 
nuclear p-p65 expression with cancer-specific survival 
observed in the full cohort is negated in patients with ER 
positive Luminal A tumours but potentiated in patients 
with ER positive Luminal B tumours, indicating that this 
association is independent of ER status. This observation 
adds to the growing body of evidence that Luminal A 
and Luminal B breast cancers should be considered as 
different diseases and may require separate therapeutic 
approaches. Currently both these patient groups receive 
endocrine therapy, with Luminal B patients having a worse 
prognosis, which is associated with an increased rate of 
endocrine resistance. The increased rate of endocrine 
resistance has previously been attributed to the presence 
of HER2 in this subtype, providing an alternative-
signalling pathway to escape the inhibitory effects of 
endocrine therapy. However, not all patients with Luminal 
B disease exhibit overexpression of HER2 suggesting that 
the increased rate in endocrine recurrence in Luminal B 
disease might have been not be solely attributed to HER2 
and might be due to an alternative mechanism in HER2 
negative cases. Luminal B tumours are categorised as ER 
or PR positive tumours with either a high proliferation 
Figure 2: (A) shows the relationship between total tumour cell p-p65 expression and cancer-specific survival in patients with primary 
operable invasive ductal breast cancer (P=0.025). (B) shows the relationship between total tumour cell p-p65 expression and cancer-specific 
survival in patients with Luminal A invasive ductal breast cancer (P=0.712). (C) shows the relationship between total tumour cell p-p65 
expression and cancer-specific survival in patients with Luminal B invasive ductal breast cancer (P=0.142). (D) shows the relationship 
between total tumour cell p-p65 expression and cancer-specific survival in patients with Triple negative invasive ductal breast cancer 
(P=0.109). (E) shows the relationship between total tumour cell p-p65 expression and cancer-specific survival in patients with HER2 
enriched invasive ductal breast cancer (P=0.992).
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Table 3: The relationship between clinicopathological characteristics and total tumour cell pp65 expression in 
patients with invasive ductal breast cancer (n=376)
low
(n=74)
high
(n=302)
P
Age (≤50/ >50 years) 21/53 87/215 0.942
Size (≤20/ 21-50/ >50 mm) 40/31/2 173/122/7 0.682
Grade (I / II / III) 18/35/21 49/11/135 0.010
Involved lymph node (negative/positive) 37/37 159/138 0.339
ER status (no/yes) 18/56 115/187 0.023
PR status (no/yes) 38/36 165/137 0.612
Her2 status (no/ yes) 62/9 238/63 0.075
Molecular subtype (Luminal A/Luminal B/triple 
negative/HER2 enriched)
39/18/11/3 126/61/69/41 0.005
Tumour necrosis (low/high) 32/40 127/169 0.813
Lymph vessel invasion (no/yes) 51/23 194/107 0.470
Blood vessel invasion (no/yes) 65/9 264/37 0.976
Klintrup–Mäkinen grade (weak/strong) 60/12 203/93 0.013
CD68+ (low/moderate/high) 20/32/21 75/108/118 0.206
CD4+ (low/moderate/high) 34/17/22 117/66/118 0.145
CD8+ (low/moderate/high) 18/31/24 81/108/112 0.840
CD138+ (low/moderate/high) 47/9/17 154/40/107 0.032
Tumour stroma percentage (low/high) 46/27 174/125 0.453
Tumour budding (low/high) 47/27 194/107 0.880
Locoregional treatment 
(lumpectomy+radiotherapy/mastectomy 
+radiotherapy)
24/50 112/190 0.456
Systemic treatment (hormonal/hormonal+ 
chemotherapy/chemotherapy/ none)
40/19/11/3 151/60/72/14 0.244
Recurrence (no recurrence/recurrence) 65/7 219/82 0.001
Bold indicates a signicant association. Number of patients with missing data is not displayed, when values do not give a sum 
of 100% this is due to data being unavailable.
Figure 3: (A) shows Western blot and plots for MCF7 cells stimulated with TNFα. (B) shows Western blot and plots for MDA-MB-231 
cells stimulated with TNFα.
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rate (Ki67 >14%) or HER2 positivity. To investigate 
if the increased rate of recurrence observed in Luminal 
B patients in the current study can be fully attributed to 
HER2 dependency and not NF-κB pathway activation, 
patients with Luminal B tumours were further divided 
into those with HER2 positive tumours or high Ki67. The 
relationship with p-p65 and cancer-specific survival was 
maintained in highly proliferative tumours and not in those 
with HER2 positive tumours. Only very small numbers 
were available for analysis, so this observation should be 
confirmed in a larger cohort but does suggest that in the 
high Ki67 subgroup, activation of the NF-κB pathway 
may also play a role in the increased rate of recurrence 
attributed to development of endocrine resistance. This in 
itself is not a novel observation as the NF-κB pathway 
has previously been associated with development of 
endocrine resistance [28–30] and NF-κB activity is 
enhanced in Tamoxifen resistant MCF7 cells compared 
to MCF7 Tamoxifen sensitive cells [28]. However, this is 
the first study to provide evidence suggesting that the NF-
κB pathway may promote recurrence in Luminal B highly 
proliferative tumours, offering an alternative therapeutic 
strategy for patients with HER2 negative Luminal B 
disease. This approach may be employed in combination 
with endocrine treatment to delay development of 
endocrine resistance or as a therapeutic option following 
development of endocrine resistance.
To further investigate this hypothesis mechanistic 
studies examining the effect and most efficient method of 
suppressing activation of NF-κB pathways are required. 
The present study investigated the impact of a reduction 
in IKKβ expression by siRNA transfection on MCF7 cell 
Figure 4: (A) shows Western blot for IKKβ and Tubulin expression in MCF7 ER positive cells, C is untreated cells, Lipo is cells treated 
only with lipofectamine, NT siRNA is cells treated with non-targeting siRNA, IKKα siRNA is cells treated with siRNA for IKKα and IKKβ 
siRNA is cells treated with siRNA for IKKβ. Western blot shows that only siRNA for IKKβ lowers IKKβ expression. (B) shows plots for 
fold change in apoptosis levels in MCF7 cells and MDA-MB-231 cells treated with lipofectamine (C) non-targeting siRNA (NT) and IKKβ 
siRNA. (C) shows plots for fold change in cell viability levels in MCF-7 cells and MDA-MB 231 cells treated with lipofectamine (C), non-
targeting siRNA (NT) and IKKβ siRNA. (D) shows xCELLigence cell index plots for MCF7 cells and MDA-MB 231 cells treated with 
lipofectamine (C), non-targeting siRNA (NT) and IKKβ siRNA.
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viability, using various methods, including assessment 
of apoptosis using an ELISA, viability using a WST-1 
assay, real time growth and viability using xCELLigence 
cell index. All modes of assessment demonstrated that 
reduction in IKKβ expression resulted in a decrease 
of cell viability. These results taken together with our 
clinical cohort results suggest that it may be beneficial to 
block NF-κB activity in ER positive Luminal B patients 
in combination with endocrine therapy or following 
development of endocrine resistance.
Although the effect we observed was potentiated 
in patients with ER positive, Luminal B disease, a trend 
towards significance was also observed in patients with 
ER, PR, HER2 negative (triple negative) disease but not 
ER negative, HER2 enriched disease. Although the trend 
did not reach significance in patients with triple negative 
disease, 10 year cancer-specific survival was stratified 
from 82% to 53%. Significance was possibly not met due 
to the study being underpowered to observe differences in 
this subtype. This is also in concordance with the in vitro 
work in the current study as high levels of phosphorylation 
of p65 was observed in ER negative MDA-MB-231 cells 
and suppression of the pathway via a reduction in IKKβ 
expression by siRNA resulted in decreased cell viability. 
This is in line with the literature where high levels of 
NF-ĸB activity have been reported in ER-negative 
tumours [28].
In addition to investigating associations between 
nuclear p-p65 expression and patient outcome measures, a 
cumulative prognostic score combining both cytoplasmic 
and nuclear p-p65 was examined. Using this cumulative 
prognostic score the current study observed that total cell 
expression was a stronger predictor of cancer-specific 
survival compared to nuclear alone and was independently 
associated with cancer-specific survival when combined 
with clinico-pathological parameters. In addition to the 
increased prognostic power observed for total tumour 
cell p-p65 compared to nuclear p-p65, total tumour cell 
p-p65 was associated with more measurements of the local 
inflammatory response. Nuclear p-p65 was only associated 
with tumour grade, tumour stroma percentage, recurrence 
and cancer-specific survival, in comparison to total tumour 
cell p-p65 being associated with tumour grade, ER status, 
molecular subtype, Klintrup-Makinen grade, CD138+ 
cells, recurrence and cancer-specific survival. This 
suggests that examining total cell p-p65 expression results 
in a more accurate, robust measurement of activated 
NF-ĸB in the tumour cell prior to or following nuclear 
translocation. Therefore total tumour cell p-p65 may be 
employed as a possible prognostic marker, or predictive 
marker for therapies targeting NF-ĸB. When stratified by 
molecular subtype, although not reaching significance, 
a trend was observed between reduced cancer-specific 
survival and total tumour cell p-p65 in the Luminal B and 
triple negative subtypes, in line with that observed for 
nuclear p-p65.
In summary, results from the present study 
demonstrate a significant role of the canonical NF-κB 
pathway in the progression of breast cancer, which appears 
to be greater in Luminal B and triple negative subtypes. 
Selective novel compounds targeting NF-ĸB pathway 
may offer a promising therapeutic approach. Furthermore, 
clinical trials should be designed incorporating predictive 
biomarkers to ensure that only subtypes known to 
respond to NF-κB intervention would receive treatment to 
maximise benefit and minimise unwanted toxicities.
MATERIALS AND METHODS
Patient cohorts
The TMA included tumour tissue samples from 
376 breast cancer patients presenting with invasive ductal 
breast cancer between 1995 and 1998 in the West of 
Scotland (at Glasgow Royal Infirmary, Glasgow Western 
Infirmary and Stobhill Hospital). Clinico-pathological 
data available included age, tumour grade, tumour size, 
lymph node status, therapy, ER, PR and HER2 status and 
Ki67 proliferation index. Information on inflammatory 
infiltrate and tumour microenvironment had previously 
been established for the cohort [18–23]. H&Es slides were 
employed to assess tumour stroma percentage (TSP) and 
Klintrup-Makinen as previously reported [19–21]. Lymph 
and blood vessel invasion (LVI and BVI, respectively) 
were assessed, using IHC staining with the lymphatic 
endothelial marker D2-40 and vascular endothelial marker 
Factor VIII as previously described [31].
Tissue microarrays (TMAs) made from formalin-
fixed paraffin-embedded tissue (FFPE) blocks which 
were retrieved from pathology archives were already 
available for this retrospective study. Tumour rich areas 
selected for construction of the TMA were identified by 
a consultant pathologist. Ethical approval for the use of 
this tissue was granted by the research Ethics Committee 
of the North Glasgow University Hospitals NHS Trust 
(NHS GG&C rec no 10/50704/60). In accordance 
with REMARK criteria, the markers examined, study 
objectives and hypothesis was described. Patient 
clinicopathological characteristics have been described, 
specimen characteristics provided, IHC methods and 
antibody specificity confirmed. Biomarkers have been 
shown in relation to prognostic variables and univariate 
and multivariate analysis applied.
Immunohistochemistry
Immunohistochemistry (IHC) was performed to 
assess protein levels of members of the NF-κB pathways; 
IKKβ and phosphorylated p65 subunit at serine 536 
of NF-κB (p-p65). TMAs were cut into 2.5μm thick 
sections, tissue was dewaxed by immersion in xylene 
and rehydrated through a series of graded alcohols. Heat 
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induced antigen retrieval was performed in a solution 
of either citrate buffer pH6 (IKKβ) or Tris EDTA buffer 
pH9 (p-p65). Tissue was then incubated in 3% hydrogen 
peroxide before non-specific binding was blocked by 
incubation in either 5% normal horse serum solution 
(Vector Laboratories; IKKβ) or 1x caesin solution 
(Vector Laboratories; p-p65,). Slides were then incubated 
in primary antibody overnight at 4°C (IKKβ, p-p65). 
Antibodies were diluted to optimal concentration in 
antibody diluent (Dako). Primary antibodies for anti-IKKβ 
was ab32135, Abcam at 1:500 and for anti p-p65 was 
ab28856, Abcam at 1:25. Staining was developed using 
EnVision™ (Dako) and 3,3’-diaminobenzidine (DAB; 
Vector Laboratories). Harris Haematoxylin counterstaining 
was performed and tissue was dehydrated and mounted 
using DPX.
Stained TMA sections were scanned using a 
Hamamatsu NanoZoomer (Welwyn Garden City, 
Hertfordshire, UK) at x20 magnification and visualization 
was carried out using Slidepath Digital Image Hub, 
version 4.0.1 (Slidepath, Leica Biosystems, Milton 
Keynes, UK). Protein expression was assessed using 
the weighted histoscore method [LB], with a second 
independent observer [JE] scoring 10% of cores and 
the interclass correlation coefficient (ICCC) calculated 
to ensure no observer bias [24]. P-p65 cytoplasmic and 
nuclear expression within the cytoplasm and nucleus were 
calculated separately.
Cell culture
MCF7 and MDA-MB-231 breast cancer cells 
were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) (Life Technologies) with 10% Fetal Bovine 
Serum (FBS) (Sigma-Aldrich), 10 Units/ml Penicillin/
Streptomycin (Life Technologies) and 1x GlutaMAX™ 
(Life Technologies) in 5% CO2 at 37°C.
Ligand exposure
Cells were seeded in 12 well plates at 1x105 cells 
per well and once 70% confluence was reached, cells were 
rendered quiescent by serum deprivation for 24 hours 
before being stimulated by exposure to 20ng/ml TNFα 
(Sigma-Aldrich) at a range of time points (5 minutes, 15 
minutes, 30 minutes, 60 minutes and 120 minutes).
Western blotting
At end of incubations/exposure to agents, cells were 
lysed in pre-heated Laemmli’s sample buffer, dispered 
by repeating passing through a 21G needle and heated at 
100oC for 5 min prior to analysis. SDS-Polyacrylamide 
Gel Electrophoresis (SDS-PAGE) was performed 
to separate proteins, which were then transferred to 
nitrocellulose membranes by electrophoretic blotting in 
wet conditions. Non-specific binding then blocked in 3% 
(w/v) BSA in NaTT buffer and membranes were incubated 
overnight, either at room temperature or 4°C, in primary 
antibody specific to the target protein diluted to optimal 
concentration in NaTT buffer containing 0.3% (w/v) 
BSA. Antibodies and dilutions used were as follows: p65 
(1:10000, sc-8008, Santa Cruz), p-p65 (1:1000, #3031, 
Cell Signaling), IκBα (1:7500, #1242, Cell Signaling), 
IKKβ (1:2500, ab32135, Abcam) and β-tubulin (at 1:5000, 
ab21058, Abcam).
Membranes were incubated in secondary HRP-
conjugated antibody (either rabbit or mouse, depending 
on primary antibody) diluted 1:10000. Enhanced 
chemiluminescence (ECL) reagent was used to detect 
presence of the antibody and X-ray films developed using 
an X-OMAT machine (Kodak) or the G:Box imaging 
system (SynGene).
Silencing
Cells were transfected with ON-TARGETplus siRNA 
(Thermo Scientific) targeting IKKβ (IKBKB, #J-003503-13). 
In order to confirm the observed effects were due to the loss 
of IKKβ and not the transfection procedure, cells were treated 
with all reagents (lipofectamine® diluted in Opti-MEM®) 
but no siRNA as a control (C) and were transfected with 
non-targeting sequence as a control (non-targeting #1, #D-
001810-01-20) (NT). IKKβ siRNA at 100 nM for all, 200 nm 
and 300 nm was delivered to the cells using lipofectamine® 
RNAiMAX (Life Technologies) diluted in Opti-MEM® 
(Life Technologies) and media was replaced with normal 
DMEM containing 10% (v/v) FCS after 6 hours. Following 
48 hours silencing, a Western blot was performed to establish 
the extent of silencing (Figure 4), extent of IKKα silencing 
was also investigated [32]. From these results a concentration 
of 200nM IKKβ siRNA was chosen as the concentrations 
used in all future experiments for both cell lines.
Apoptosis and cell viability assays
After knockdown of mRNA expression, cells were 
plated for apoptosis or cell viability assays. Apoptosis 
levels were assessed using a Cell Death Detection enzyme-
linked immunosorbent assay kit (Roche) and for cell 
viability using the water-soluble tetrazolium salt (WST-1) 
reagent (Roche). Cells were seeded in a 96 well plate at 
a density of 5x103 cells/well in 100μL of standard culture 
medium. Once a confluency of 60-70% was reached cells 
were exposed to siRNA for 48 hours and the assays then 
performed following manufacturer’s instructions. Assays 
were performed in triplicate and error bars representing 
standard deviation added to graphs. Fold change was 
compared to control.
Cell viability via xCELLigence
The xCELLigence machine (ACEA Biosciences, 
San Diego) was used to display cell growth and viability in 
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real time following silencing of IKKβ. With this method, 
measurements are continuously sent to the computer, 
allowing for real time growth curves to be plotted using 
“Cell Index” which represents the number and viability 
of the cells [25]. Cells were seeded in a 96 well E-plate™ 
(ACEA Biosciences, San Diego) at 3x103 cells/well with 
200μl of media in each well, grown for two days to ensure 
log phase of growth before treatment with siRNA and after 
72 hours graphs showing cell index over time were drawn.
Statistical analysis
Statistics was performed using IBM SPSS version 
21. Kaplan-Meier curves were constructed for cancer-
specific survival, the log rank test was employed to 
compare high and low expression. Hazard ratios were 
calculated using Cox regression with 95% confidence 
intervals. Cox regression multivariate analysis was also 
performed with the inclusion of known predictive factors. 
Inter-relationships between variables were assessed using 
contingency tables with the chi-squared test for trend as 
appropriate. Values of P<0.05 were considered statistically 
significant.
Statistical analysis for apoptosis and cell viability 
assays was performed using a two-way ANOVA with 
Bonferroni correction and Dunnett’s test. P values were 
considered significant if P<0.05 and highly significant if 
P<0.001.
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